Dashboard
Manage Tickers

AMLX Amylyx Pharmaceuticals, Inc.

Nasdaq amylyx.com


$ 14.50 $ -0.14 (-0.98 %)    

Friday, 24-Oct-2025 18:05:18 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 14.17
$ 14.52
$ 13.98 x 50
$ 14.60 x 9
$ 14.03 - $ 14.61
$ 2.60 - $ 16.96
860,761
na
1.26B
$ 1.18
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-04-2025 01-01-1970 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

citigroup-maintains-buy-on-amylyx-pharmaceuticals-raises-price-target-to-20
Citigroup Maintains Buy on Amylyx Pharmace...
10/17/2025 15:21:27

Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $...

baird-maintains-outperform-on-amylyx-pharmaceuticals-raises-price-target-to-19
Baird Maintains Outperform on Amylyx Pharm...
10/16/2025 11:30:20

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from ...

b-of-a-securities-maintains-buy-on-amylyx-pharmaceuticals-raises-price-target-to-16
B of A Securities Maintains Buy on Amylyx ...
10/03/2025 13:06:10

B of A Securities analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price targe...

goldman-sachs-maintains-buy-on-amylyx-pharmaceuticals-raises-price-target-to-20
Goldman Sachs Maintains Buy on Amylyx Phar...
09/16/2025 16:41:28

Goldman Sachs analyst Corinne Johnson maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target ...

guggenheim-maintains-buy-on-amylyx-pharmaceuticals-raises-price-target-to-25
Guggenheim Maintains Buy on Amylyx Pharmac...
09/15/2025 12:33:07

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target fr...

amylyx-pharmaceuticals-prices-175m-underwritten-public-offering-of-175m-shares-of-common-stock-at-10-per-share
Amylyx Pharmaceuticals Prices $175M Underw...
09/10/2025 06:23:50

amylyx-pharmaceuticals-announces-an-underwritten-public-offering-of-its-common-stock-financial-terms-not-disclosed
Amylyx Pharmaceuticals Announces An Underw...
09/09/2025 20:03:25

Amylyx Pharmaceuticals (NASDAQ:AMLX) Has Initiated An Underwritten Public Offering Of Its Common Stock, With All Shares Being O...

reported-earlier-amylyxs-withdrawn-from-market-relyvrio-has-failed-to-make-an-impact-on-primary-or-secondary-endpoints-in-a-rare-neurodegenerative-disease-prompting-the-company-to-discontinue-the-program---fiercebiotech
Reported Earlier: 'Amylyx's Withdrawn-From...
08/28/2025 16:09:12

https://www.fiercebiotech.com/biotech/amylyx-axes-rare-disease-program-after-relyvrio-fails-beat-placebo#:~:text=Amylyx%20axes%...

b-of-a-securities-maintains-buy-on-amylyx-pharmaceuticals-raises-price-target-to-14
B of A Securities Maintains Buy on Amylyx ...
08/28/2025 15:47:56

B of A Securities analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price targe...

fda-withdrawing-approval-of-nda-for-relyvrio-for-suspension-3gpacket-1-gpacket-held-by-amylyx-pharmaceuticals---federal-register
'FDA Withdrawing Approval Of NDA For Relyv...
08/28/2025 13:10:42

https://www.federalregister.gov/public-inspection/2025-16646/withdrawal-of-approval-of-new-drug-application-amylyx-pharmaceutic...

amylyx-halts-rare-brain-disorder-drug-program-after-disappointing-trial
Amylyx Halts Rare Brain Disorder Drug Prog...
08/27/2025 16:24:53

Amylyx ends its PSP trial for AMX0035 after no efficacy was seen and turns its focus to avexitide and ALS research, expecting d...

amylyx-pharma-to-discontinue-orion-program-of-amx0035-in-adults-living-with-progressive-supranuclear-palsy
Amylyx Pharma To Discontinue ORION Program...
08/27/2025 11:15:33

- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24- AMX0035 continued to be gen...

amylyx-pharma-q2-eps-046-misses-045-estimate
Amylyx Pharma Q2 EPS $(0.46) Misses $(0.45...
08/07/2025 11:01:04

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.4...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

amylyx-drug-slashes-sugar-spikes-post-weight-loss-surgery
Amylyx Drug Slashes Sugar Spikes Post-Weig...
07/14/2025 18:15:11

Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric ...

reported-sunday-amylyx-highlights-efficacy-and-24-hour-coverage-of-avexitide-90-mg-daily-supports-advancing-phase-3-lucidity-trial
Reported Sunday, Amylyx Highlights Efficac...
07/14/2025 06:47:50

Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy...

goldman-sachs-reinstates-buy-on-amylyx-pharmaceuticals-announces-10-price-target
Goldman Sachs Reinstates Buy on Amylyx Pha...
07/10/2025 18:12:58

Goldman Sachs analyst Corinne Johnson reinstates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and announces $10 price tar...

amylyx-to-spotlight-breakthrough-hypoglycemia-drug-avexitide-at-endo-2025-investor-event
Amylyx to Spotlight Breakthrough Hypoglyce...
07/08/2025 11:03:09

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced that it will host an inv...

amylyx-eyes-2b-opportunity-in-post-surgery-sugar-crash-market
Amylyx Eyes $2B Opportunity In Post-Surger...
06/24/2025 18:59:09

Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ m...

carnival-posts-better-than-expected-earnings-joins-liminatus-pharma-coinbase-global-uber-and-other-big-stocks-moving-higher-on-tuesday
Carnival Posts Better-Than-Expected Earnin...
06/24/2025 16:30:26

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION